How Desmopressin Test Helps Diagnose Cushing Syndrome
The desmopressin test can help distinguish true Cushing syndrome from pseudo-Cushing syndrome (non-neoplastic hypercortisolism) with high specificity, but it is NOT recommended for routine diagnostic use according to current guidelines.
Guideline Recommendations
The 2008 Endocrine Society guidelines explicitly suggest against the use of the desmopressin test, except in research studies, until additional data validate its utility 1. However, the more recent 2021 Lancet consensus guideline acknowledges evolving evidence, noting that the desmopressin test has shown good diagnostic performance in distinguishing Cushing syndrome from pseudo-Cushing syndrome in some studies 2.
Mechanism and Rationale
The test exploits a key biological difference:
- ACTH-secreting pituitary adenomas (Cushing disease) express vasopressin V1b (V3) receptors, which respond to desmopressin with a paradoxical rise in plasma ACTH and cortisol 2
- Normal individuals and those with pseudo-Cushing syndrome show minimal or no ACTH/cortisol response to desmopressin 3
- This paradoxical response occurs because neoplastic ACTH-producing cells upregulate vasopressin type 3 receptors and/or aberrantly express type 2 receptors 3
Clinical Performance
For Distinguishing Cushing Disease from Pseudo-Cushing Syndrome:
Recent research demonstrates strong diagnostic accuracy 2:
- Sensitivity: 88% (95% CI: 0.79-0.93)
- Specificity: 94% (95% CI: 0.86-0.97) 4
A 2015 prospective study of 124 patients found that an ACTH peak ≥71.8 pg/mL or absolute ACTH increment ≥37 pg/mL achieved:
- Sensitivity: 88-91%
- Specificity: 94-96%
- Positive predictive value: 95.3% 5
For Distinguishing Cushing Disease from Ectopic ACTH Syndrome:
The test performs less reliably here 3, 4:
- Sensitivity: 81-88%
- Specificity: 64-80%
- 15-20% of Cushing disease patients would be misclassified as having ectopic ACTH syndrome 4
Practical Application
When to Consider Using It:
- Equivocal initial screening tests (mildly elevated UFC, borderline dexamethasone suppression test) where pseudo-Cushing syndrome is suspected 2
- As an adjunct to dexamethasone-CRH testing when both tests are performed together, they show excellent agreement 2
- During bilateral inferior petrosal sinus sampling (BIPSS) to enhance diagnostic accuracy when CRH is unavailable 6
- Special populations like pregnancy where standard testing is complicated 7
Test Protocol:
- Administer 10 μg desmopressin IV
- Measure ACTH and cortisol at baseline and post-injection (typically at 15,30, and 60 minutes)
- Peak response occurs within 3-5 minutes in 98-100% of responders 6
Interpretation Cutoffs:
Multiple cutoff values have been proposed 4:
- ΔACTH >35-50% from baseline
- Δcortisol >20% from baseline
- Combined criteria (both ACTH and cortisol increases) improve specificity
Important Caveats
The desmopressin test has high specificity for Cushing disease but lacks consensus on standardized cutoff values 8. Different studies use varying protocols, doses, and interpretation criteria, limiting generalizability 2.
The 2021 guideline notes the test is less complex and expensive than the dexamethasone-CRH test while maintaining comparable diagnostic performance 2. However, it should not replace standard first-line screening tests (late-night salivary cortisol, 24-hour urinary free cortisol, or overnight dexamethasone suppression test).
Bottom Line Algorithm
For patients with suspected Cushing syndrome:
- Start with standard screening tests (DST, UFC, or LNSC) 2
- If results are mildly elevated or equivocal and pseudo-Cushing syndrome is suspected, consider desmopressin test as an adjunct 2
- Do not use it as a first-line test or rely on it alone for diagnosis 1
- Do not use it to differentiate Cushing disease from ectopic ACTH syndrome due to insufficient accuracy 3, 4
- Consider it during BIPSS when CRH is unavailable 6